Comparative Pharmacology
Head-to-head clinical analysis: TRANXENE versus XANAX XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRANXENE versus XANAX XR.
TRANXENE vs XANAX XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzodiazepine; enhances GABA-A receptor activity by binding to benzodiazepine site, increasing chloride ion influx and neuronal hyperpolarization.
Benzodiazepine that enhances GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and reduced excitability.
7.5 mg to 15 mg orally 2 to 4 times daily; maximum dose 90 mg/day.
0.5-1 mg orally once daily; may increase at 3-4 day intervals; maximum 10 mg/day
None Documented
None Documented
Terminal elimination half-life of the active metabolite desmethyldiazepam is 30-200 hours (mean ~100 hours); parent drug clorazepate is rapidly hydrolyzed and has negligible half-life. Accumulation occurs with repeated dosing, leading to delayed peak effects and prolonged sedation.
Mean terminal elimination half-life is 11.2 hours (range 6.3-15.8 hours). The extended-release formulation provides sustained therapeutic concentrations with once-daily dosing.
Primarily renal (80-90% as conjugated metabolites, including oxazepam and desmethyldiazepam); biliary/fecal excretion accounts for <10%.
Renal excretion of unchanged drug and metabolites accounts for approximately 80-90% of the dose. Fecal excretion is minimal (<10%).
Category C
Category C
Benzodiazepine Anxiolytic
Benzodiazepine Anxiolytic